Page 6 of 7 FirstFirst 1234567 LastLast
Results 51 to 60 of 61

Thread: ReNetX Bio Launched to Advance Innovative Neuro-Regenerative Technology Developed at

  1. #51
    Quote Originally Posted by GRAMMY View Post
    • Inside a muscle there are groups of motor units separated by membranes. Each motor unit consists of a single neuron and all of the muscle fibers it stimulates. In muscles such as the hand where fine motor control is necessary the ratio of nerves to fibers will be much higher than that of a muscle such as the calf.
    Thanks, that explains it in a lot more detail.

  2. #52
    Senior Member
    Join Date
    Apr 2016
    Location
    Cincinnati, Ohio, USA
    Posts
    2,535
    Quote Originally Posted by GRAMMY View Post
    • Inside a muscle there are groups of motor units separated by membranes. Each motor unit consists of a single neuron and all of the muscle fibers it stimulates. In muscles such as the hand where fine motor control is necessary the ratio of nerves to fibers will be much higher than that of a muscle such as the calf.
    Grammy to the rescue as usual!
    Thank you.
    T3 complete since Sept 2015.

  3. #53
    To be super simple about cervical decisions... If I were hoping to see a bit of efficacy with a tiny dose of new product in a Ph. 1 safety trial, I'd chose the patient working at some finger twitching over trying to lift up a heavy leg any day.

  4. #54
    Added
    Sven Jacobson
    to their advisory board.

    “Sven has deep experience in developing treatments for central nervous system injuries, including spinal cord injury,” says ReNetX CEO Erika Smith. “He can provide real insight into designing clinical trials that provide investors with the data they need.”
    https://globenewswire.com/news-relea...ory-Board.html

  5. #55
    Senior Member
    Join Date
    Dec 2016
    Location
    Houston, Texas
    Posts
    184
    UPDATE:

    https://globenewswire.com/news-relea...Symposium.html

    NEW HAVEN, Conn., April 10, 2018 (GLOBE NEWSWIRE) -- Thanks to the promise of its NoGo Trap therapeutic for treating chronic spinal cord injury (SCI), New Haven-based startup ReNetX Bio has been invited to present as part of a ?Clinical Trials 360? symposium at the upcoming American Spinal Cord Injury Association (ASIA) meeting. The NoGo Trap blocks inhibitors in the central nervous system thereby allowing the body to repair itself by re-growing nerve fiber connections. The company was invited ?based on the promise and uniqueness of our treatment for spinal cord injury,? says ReNetX President and CSO George Maynard. Unlike many other treatments attempting to address acute injury, the NoGo Trap trial will focus on chronic patients who have an injury beyond one year. The breakthrough technology developed in Dr. Stephen Strittmatter?s laboratory at Yale has an entirely new approach that has shown successful restoration of neurons in animal studies many months after spinal cord injury.
    The purpose of the ?Clinical Trials 360? symposium is to share developments in the pipeline for restorative interventions in SCI with attendees?to reach thought leaders and drive interest among researchers. The ASIA meeting will be held in Rochester, Minnesota, May 2-4. ?The symposium will highlight interventional treatments at various stages of injury,? says ReNetX CEO Erika R. Smith. ?We?re honored to be among the presenters and to share our discovery of a new approach for treating chronic SCI by targeting the Nogo receptor.?
    ReNetX will be submitting an IND (Investigational New Drug) to the Food and Drug Administration and will then move forward to a clinical trial for its lead candidate by the end of 2018. There are approximately 300,000 in the U.S. suffering from chronic SCI. ?Those with chronic spinal cord injuries live with severe impairment,? says Maynard. ?Any improvement in their ability to function would be a fantastic step forward.?
    Maynard, who will speak at the symposium, has more than 27 years of pharmaceutical and research experience. A chemist by training, he spent the first half of his career developing small molecules for Hoescht (now part of Sanofi) and then as Vice President of Early Development at Neurogen Corporation where he led pre-clinical development for emerging therapeutics.
    He says that joining ReNetX offered an opportunity to get involved in launching a therapeutic that ?wasn?t just an incremental improvement on existing drugs, but had the potential to be groundbreaking.? If their approach of targeting inhibitory factors is successful, Maynard says, ?it will open the floodgates to other approaches being aggressively funded to impact therapies for other disease or injury to the central nervous system.?

  6. #56
    Senior Member lunasicc42's Avatar
    Join Date
    Oct 2004
    Location
    Lutz, Fl USA*********C456
    Posts
    2,305

    ReNetX Bio Announces Initiation Of Patient Dosing In The First Phase One Clinical...

    "That's not smog! It's SMUG!! " - randy marsh, southpark

    "what???? , you don't 'all' wear a poop sac?.... DAMNIT BONNIE, YOU LIED TO ME ABOUT THE POOP SAC!!!! "


    2010 SCINet Clinical Trial Support Squad Member
    Please join me and donate a dollar a day at http://justadollarplease.org and copy and paste this message to the bottom of your signature

  7. #57
    Senior Member
    Join Date
    Dec 2016
    Location
    Houston, Texas
    Posts
    184
    UPDATE:

    http://www.globenewswire.com/news-re...-AXER-204.html

    August 14, 2019 09:02 ET | Source: ReNetx Bio


    NEW HAVEN, Conn., Aug. 14, 2019 (GLOBE NEWSWIRE) -- ReNetX Bio, Inc., a leading biotechnology company committed to reversing disease and damage for patients suffering from central nervous system (CNS) disorders, has announced a successful first patient dosing in a Phase 1 clinical trial of its lead drug candidate, fusion protein AXER-204.

    Axonal loss is a common, yet unaddressed pathology, in a broad range of chronic and acute diseases of the central and ocular nervous systems. AXER-204 is the first in a new class of therapy designed to remove inhibitory proteins from the CNS environment allowing for axonal regrowth and increased plasticity. These changes harness the body’s ability to regenerate new neural connections through rewiring. “Given the promising results seen in preclinical studies, it is our hope that AXER-204 will become the first therapeutic shown to restore function and reverse damage in spinal cord injury and other CNS diseases,” says ReNetX President and CSO George Maynard, PhD.
    The Phase 1 open-label, dose escalation “RESET” trial will evaluate the safety, tolerability, and pharmacokinetics of AXER-204 in patients with chronic spinal cord injury and is expected to enroll approximately 24 patients. An estimated 300,000 people are currently living with chronic spinal cord injury in the U.S., and there is currently no approved therapeutic to restore sensory or motor function after injury. The company was founded by Stephen Strittmatter, MD, PhD, Vincent Coates Professor of Neurology at Yale University.
    About the Phase 1 RESET Study: For more information, please visit ClinicalTrials.gov.
    About ReNetX Bio, Inc.: For more information, please visit www.renetx.com.

    Email that was sent out!

    "We are excited to share our news that AXER-204 has entered the clinic with successful patient dosings in our Phase 1 trial for chronic spinal cord injury. We are on our way, gathering important safety, tolerability, and pharmacokinetic data to further our understanding of our novel molecule that we hope will become the first therapeutic shown to restore function and reverse damage in spinal cord injury and other CNS diseases.

    For those possibly interested in participating in the "RESET" trial, we have made some updates broadening our enrollment criteria, including removing the 10 year limit since time of injury. Please refer to our ClinicalTrials.gov listing for more details.

    Thank you for your interest, we will keep you in the loop as we continue to advance.

    The ReNetX Bio Team"


  8. #58
    Great news
    "I'm manic as hell-
    But I'm goin' strong-
    Left my meds on the sink again-
    My head will be racing by lunchtime"

    <----Scott Weiland---->

  9. #59
    Senior Member
    Join Date
    Dec 2016
    Location
    Houston, Texas
    Posts
    184
    Have any of you applied?

  10. #60
    This sounds so great

    "The Phase 1 open-label, dose escalation “RESET” trial will evaluate the safety, tolerability, and pharmacokinetics of AXER-204 in patients with chronic spinal cord injury and is expected to enroll approximately 24 patients."
    "I'm manic as hell-
    But I'm goin' strong-
    Left my meds on the sink again-
    My head will be racing by lunchtime"

    <----Scott Weiland---->

Similar Threads

  1. iPS cell technology in regenerative medicine.
    By wildwilly in forum Stem Cell Research
    Replies: 0
    Last Post: 08-18-2010, 08:42 PM
  2. Innovative equipment technology
    By Eileen in forum Equipment
    Replies: 0
    Last Post: 06-08-2009, 10:50 AM
  3. Replies: 0
    Last Post: 04-23-2009, 10:17 PM
  4. Replies: 11
    Last Post: 03-14-2007, 04:29 PM
  5. Replies: 2
    Last Post: 05-10-2003, 08:36 AM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •